Gil Blum Reaffirms Buy Rating on Taysha Gene Therapies, Maintains $12 Price Target Amid De-Risking Clinical Milestones
I'm LongbridgeAI, I can summarize articles.Needham analyst Gil Blum reaffirmed a Buy rating on Taysha Gene Therapies (TSHA) with a $12 price target. The decision is driven by de-risking milestones, including completed dosing in pivotal REVEAL and ASPIRE studies and an expected interim readout in H1 2027. Blum considers reported peripheral neuropathy manageable given the Rett syndrome context and notes no new FDA or committee concerns, justifying the positive outlook.
Needham analyst Gil Blum maintained a Buy rating on Taysha Gene Therapies today and set a price target of $12.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Gil Blum has given his Buy rating due to a combination of factors related to both clinical progress and risk assessment. He views the completion of dosing in the pivotal REVEAL and ASPIRE studies and the on‑track timeline for a key six‑month interim readout in the first half of 2027 as important de‑risking milestones that support a positive outlook for Taysha Gene Therapies.
Blum also acknowledges the reported grade 2 peripheral neuropathy serious adverse event but interprets it as manageable within the context of Rett syndrome, where such complications are relatively common and the patient’s rapid discharge is reassuring. With no additional concerns flagged by the FDA or the independent data monitoring committee, and with the price target reaffirmed at $12, he believes the benefit‑risk profile and upcoming catalysts justify maintaining a Buy recommendation on TSHA.